Reproducibility of exhaled nitric oxide measurements in overweight and obese adults

Willemien Thijs1*, Renée de Mutsert2, Saskia le Cessie2,3, Pieter S Hiemstra1, Frits R Rosendaal2, Saskia Middeldorp4 and Klaus F Rabe5

Abstract
Background: Exhaled nitric oxide is a noninvasive measure of airway inflammation that can be detected by a handheld device. Obesity may influence the reproducibility of exhaled nitric oxide measurements, by – for instance – decreased expiratory reserve volume.

Findings: We analyzed triple exhaled nitric oxide measurements from 553 participants (aged 45 to 65 years with a body mass index \( \geq 27 \text{ kg/m}^2 \)) of the Netherlands Epidemiology of Obesity Study. The interclass correlation coefficient (single measurement reliability) was 0.965 (95% CI: 0.960, 0.970).

Conclusions: We conclude that for assessment of exhaled nitric oxide in large cohorts of overweight and obese adults a single measurement suffices.

Keywords: Reproducibility, Exhaled nitric oxide, Obesity

Findings
Introduction
Exhaled nitric oxide (eNO) is a noninvasive marker of inflammation in the airways. The levels of eNO correlate well with other markers of inflammation in the airways of asthmatics, such as sputum eosinophils and airway eosinophilia in bronchial biopsies [1,2]. Measuring eNO with a handheld device is a convenient way to assess airways inflammation and has been used to study e.g. occupational hazards or asthma [3,4]. The prevalence of obesity has risen dramatically in the past decades and an increasing proportion of participants in studies will be overweight or obese [5]. Because eNO measurements take time and generate costs it is important to establish the reproducibility of eNO measurements in overweight and obese adults.

How could obesity influence eNO measurements? Obesity is associated with a loss in expiratory reserve volume [6], which may influence eNO measurement that require a slow and steady exhalation. In addition, obesity is associated with low grade systemic inflammation [7] which may be accompanied by airways inflammation resulting in increased eNO levels. However, studies into the association between obesity and levels of eNO show conflicting results [8-11]. Therefore it is not clear whether putatively increased eNO levels may contribute to decreased reproducibility in obese subjects.

The ATS/ERS recommendations for eNO measurements suggest two measurements of eNO [12]. Because of the time requirement and costs associated with multiple eNO measurements in large scale studies, a single measurement would be preferable. Reproducibility of eNO measured by the handheld NIOX MINO has been evaluated in children [13], adults [14], asthma patients and pregnant women [15], but not in overweight and obese individuals. Therefore, we used a triplicate measurement to assess the reproducibility of eNO measured by a handheld NIOX MINO in a cohort study of overweight and obese adults, with the aim to assess whether a single measurement may suffice in large scale studies.

Materials and methods
The Netherlands Epidemiology of Obesity (NEO) Study is a population-based cohort study in adults aged 45 to 65 years, with an oversampling of participants with overweight or obesity [16]. The study was approved by the ethical committee of the Leiden University Medical Center and all participants gave written informed consent.

* Correspondence: W.Thijs@lumc.nl
1Department of Pulmonology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, the Netherlands
Full list of author information is available at the end of the article

© 2014 Thijs et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The present analysis includes the first 630 participants with a body mass index (BMI) ≥ 27 kg/m². Completed multiple questionnaires including self-reported asthma, and anthropometric and maximal flow-volume curves measurements were obtained. Exhaled nitric oxide was measured using a portable analyzer, the NIOX MINO (Aerocrine AB, Solna, Sweden). Participants performed a 10 seconds slow steady exhalation. Three successive recordings at 1-minute intervals, expressed as parts per billion (ppb), were made. The interclass correlation coefficient (ICC) was calculated for the three measurements in all participants, participants with self reported asthma and separately for participants with a BMI ≥ 35 and for elevated mean eNO levels (>25 ppb and for >50) [17]. The mean intra-participant difference in eNO was calculated and a Bland-Altman plot was constructed. Statistical analyses were performed with SPSS 20.0 software (SPSS Inc., Chicago, IL).

Results

Of the first 630 participants of the NEO study, 46 participants did not perform eNO measurements because they did not visit the lung function department due to logistic problems. In another 31 patients, no measurements were obtained because of inability to perform the technique or because of a technical failure with the nitric oxide machines. As a result, the present analysis includes 553 participants who performed all three eNO measurements. The characteristics of the study population and results of eNO measurements are presented in Table 1.

The ICC (single measurement reliability) for all participants was 0.965 (95% CI: 0.960, 0.970), whereas it was 0.926 (95% CI: 0.926, 0.965) for the participants with a BMI ≥ 35 (n = 92). The ICC (single measurement reliability) for all participants with asthma (n = 39) was 0.988 (95% CI: 0.979, 0.993), whereas it was 0.932 (95% CI: 0.818, 0.981) for the participants with asthma and a BMI ≥ 35 (n = 10). The ICC for all eNO measurements that exceeded 25 ppb (n = 109) was 0.949 (95% CI: 0.931,
0.963) and for those that exceeded 50 ppb (n = 18) was 0.911 (95% CI: 0.818, 0.963). The mean intra-participant difference in eNO for all participants was for the second and first reading: -0.05 ppb (95% CI: -0.714, 0.704); third and first reading -0.15 ppb (95% CI: -6.8, 7.6); and third and second reading -0.13 ppb (95% CI: -5.9, 6.5). A Bland-Altman plot was constructed for the first two measurements (Figure 1).

Discussion

The ICC and mean intra-participant difference in eNO for all 553 participants was in line with previous reproducibility studies performed on the NIOX MINO in other populations [13,14]. The ICC for participants with a BMI ≥ 35 kg/m² was slightly lower (but clinically not relevant) than within the whole group, possibly as a result of decreased expiratory reserve volumes. Low grade inflammation associated with obesity appears a less likely explanation for the small loss in reproducibility because only early studies report a positive correlation between BMI and eNO [8,9]; later studies have not been able to reproduce these initial findings [10,11]. The reproducibility in participants with self reported asthma was in line with the results in the whole group but within our study the reproducibility at higher eNO levels was slightly lower. In earlier study by Selby et al. [13] it is concluded that for individual absolute levels two measurements are needed. Similarly, we conclude that in clinical practice two eNO measurements are advised but despite small differences of ICC in different analyses, our results demonstrate that in large cohorts of overweight and obese adults a single eNO measurement suffices, which will have significant logistical and financial consequences for cohort studies.

Abbreviations

BMI: Body mass index; ICC: Inter class correlation; eNO: Exhaled nitric oxide; Ppb: Parts per billion; NED: Netherlands Epidemiology of Obesity; FEV1: %: Percent predicted of forced expiratory volume; FVC: %: Percent predicted of forced vital capacity; ATS: American Thoracic Society; ERS: European Respiratory Society.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

WT participated in the design, performed the statistical analysis and drafted the manuscript. RM participated in the design, helped to draft the manuscript and made suggestions for the analyses. SC supervised the statistical analyses. SM, FR, PH and KR conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Supported by an unrestricted research grant from Astra-Zeneca NL.

Author details

1Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands. 2Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 3LungenClinic Grosshansdorf, Grosshansdorf, Germany.

Received: 20 December 2013 Accepted: 10 October 2014
Published: 3 November 2014

References

1. Jatakanon A, Lim S, Kartonov SA, Chung KF, Barnes PJ: Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998, 53:91–95.
2. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A: Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001, 164:1376–1381.
3. Sordillo JE, Webb T, Kwan D, Karmel J, Hoffman E, Milton DK, Gold DR: Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma. J Allergy Clin Immunol 2011, 127:161–167.
4. Tunug AM, Bratveit M, Mamuya SD, Moen BE: Fractional exhaled nitric oxide among cement factory workers: a cross sectional study. Occup Environ Med 2013, 70:289–295.
5. WHO: Obesity. Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva: World Health Organization; 2000:984.
6. Littleton SW: Impact of obesity on respiratory function. Respir Med 2012, 127:43–49.
7. Tilg H, Moschen AR: Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Cln Sci (Lond) 2008, 114:275–288.
8. Depalo A, Caragnano GE, Spanevello A, Sabato R, Cagnazzo MG, Gramiccioni C, Foschino-Barbaro MP: Exhaled NO and iNOS expression in sputum cells of healthy, obese and OSA subjects. J Intern Med 2008, 263:70–78.
9. Maestrelli P, Ferrari Zani S, Visentin A, Mariani E, Dal BD, Accordino F, Fabbri LM: Measurement of exhaled nitric oxide in healthy adults. Sarcoidosis Vasc Diffuse Lung Dis 2007, 24:65–69.
10. Kim SH, Kim TH, Lee JS, Koo TY, Lee CB, Yoon HJ, Shin DH, Park SS, Sohn JW: Adiposity, adipokines, and exhaled nitric oxide in healthy adults without asthma. J Asthma 2011, 48:177–182.
11. Lombardi C, Gargioni S, Gardini A, Canonica GW, Passalacqua G: Impact of bariatric surgery on pulmonary function and nitric oxide in asthmatic and non-asthmatic obese patients. J Asthma 2011, 48:553–557. doi:10.3109/02770903.2011.587581. Epub 2011 Jun 28.
12. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912–930.
13. Selby A, Clayton B, Grundy J, Pike K, Drew K, Raza A, Kurukulaaratchy R, Arshad SH, Roberts G: Exhaled nitric oxide measurements using the portable NIOX MINO repeatable? Respir Res 2010, 11:43.
14. Alving K, Janson C, Nordvall L: Exhaled NO and iNOS expression in sputum cells of healthy, obese and OSA subjects. J Intern Med 2008, 263:70–78.
15. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC: Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006, 61:817–827.

doi:10.1186/1756-0500-7-775

Cite this article as: Thijis et al.: Reproducibility of exhaled nitric oxide measurements in overweight and obese adults. BMC Research Notes 2014 7:775.